US-based Sadra Medical, a developer of new therapies for the treatment of aortic valve disease, has raised $30m in new investment capital. The round was led by Accuitive Medical Ventures, and includes existing investors Boston Scientific, Finistere, Firstmark Capital, Oakwood, ONSET Ventures, and SV Life Sciences.
Sadra is developing technical and clinical advancements to an aortic valve replacement procedure called ‘percutaneous aortic valve replacement’ (PAVR), during which a valve prosthesis can be positioned in a patient’s heart by means of a catheter navigated through the patient’s arteries. Sadra’s breakthrough is a technology it calls the Lotus valve system, the first fully repositionable prosthesis for percutaneous aortic valve replacement.
According to Sadra, the Lotus valve system allows interventional cardiologists to easily navigate a technically-advanced prosthesis to the delivery site, and to precisely control its placement, without interruption to the patient’s normal circulatory processes.
Ken Martin, Sadra Medical’s president and CEO, said: We have had very successful European clinical experiences with our Lotus Valve System. We’ve confirmed through the physician and patient experience that we are firmly on the right track, and are designing even more improvements in functionality and user-friendliness as we move to bring the system to commercial viability.